Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.

Saved in:

Bibliographic Details
Title:	Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials.
Authors:	Shaya S; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom., Uche-Ikonne O; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom., Kilerci B; Cancer Research UK Manchester Institute, Manchester, United Kingdom., Stevenson J; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Greystoke A; Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom.; Newcastle University, Newcastle upon Tyne, United Kingdom., Cook N; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Thistlethwaite FC; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Carter L; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Graham DM; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom., Krebs MG; The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom.
Source:	Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2025 Aug 25; Vol. 8 (3), pp. 222-232. Date of Electronic Publication: 2025 Aug 25 (Print Publication: 2025).
Publication Type:	Journal Article
Journal Info:	Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: In Process
Database:	MEDLINE Ultimate

Description
ISSN:	2590-017X
DOI:	10.36401/JIPO-25-11